Coverage
Filings
Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).
| 26 Sept 2011 |
| 400,000 Orion A-shares converted into B-shares | 23 Sept 2011 |
| Orion receives European marketing authorisation for dexdor® | 21 Sept 2011 |
| Composition of the Nomination Committee of Orion Corporation | 21 Sept 2011 |
| 400,000 Orion A-shares converted into B-shares | 14 Sept 2011 |